Latest Ensysce Biosciences News & Updates

See the latest news and media coverage for Ensysce. We track all announcements, press releases, and industry mentions in real time, all in one place.

Ensysce Biosciences (Ensysce)

Biotech company developing abuse-deterrent opioid therapies

ensysce.com

Headquarters: La Jolla, United States
Founded year: 2008
Company type: Public company
Number of employees: 10–50
Industry: Pharmaceuticals

Last updated Today

Latest news about Ensysce Biosciences (Ensysce)

In short: Ensysce advanced its clinical-stage overdose-protection opioid programs while securing federal funding and addressing compliance issues.

Company announcements

August 3 Ensysce

Ensysce describes PF614-MPAR's automatic overdose protection.

The opioid reduces exposure above therapeutic thresholds, holds FDA Breakthrough Therapy designation, and addresses 80,000 annual U.S. overdose deaths with NIDA support.

July 6 Ensysce

Ensysce receives FDA Breakthrough Therapy designation for PF614-MPAR

The FDA recognized it as a substantial improvement over existing therapies for oral overdose protection. Ensysce has enrolled the first patient in Part 3 of the PF614-MPAR-102 study.

June 22 Ensysce

Ensysce's PF614-MPAR has received FDA Breakthrough Therapy designation

It is the only opioid to receive this designation for oral overdose protection, with MPAR technology built into the molecule. Ensysce is working to bring it to clinical reality.

April 19 Ensysce

Ensysce obtains IRB approval for final study part

Part 3 of PF614-MPAR-102 is the last stage, building on prior reduced opioid exposure results and moving closer to a complete dataset for MPAR overdose-protection.

Media coverage

August 6 Investing.com

Form 8K Ensysce Biosciences Inc For: 6 August By Investing.com

Redwire’s SpaceMD to fly 32 research units on SpaceX Starfall in 2028 · SpaceX says Terafab to be built in Texas with initial investment of...

August 4 Yahoo Finance

Ensysce Biosciences Stock Doubles In One Trading Session - Here s Why

Ensysce Biosciences, Inc (NASDAQ:ENSC) stock gained almost 100% with a strong session volume...

July 17 Morningstar

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant | Morningstar

Funds Advance FDA-Designated Breakthrough Therapy First-in-Class Opioid with Oral Overdose-Protection · SAN DIEGO, CA / ACCESS Newswire / July 14, 2026 / Ensysce Biosciences, Inc.

July 14 The Globe and Mail

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

Detailed price information for Ensysce Biosciences Inc (ENSC-Q) from The Globe and Mail including charting and trades.

Never miss news about Ensysce

Track Ensysce and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.